Compare
Acumen Pharmaceuticals, Inc. vs Humacyte, Inc. vs Quince Therapeutics, Inc. vs Editas Medicine, Inc.
| Latest fiscal year | Acumen Pharmaceuticals, Inc. ABOS | Humacyte, Inc. HUMA | Quince Therapeutics, Inc. QNCX | Editas Medicine, Inc. EDIT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.04M | n/a | $40.52M |
| Revenue growth (YoY) | n/a | n/a | n/a | +25.4% |
| Gross margin | n/a | -376.1% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | n/a | -394.9% |
| Net margin | n/a | n/m | n/a | -395.0% |
| Net income | -$121.33M | -$40.83M | -$83.98M | -$160.06M |
| EPS (Diluted) | -$2.00 | -$0.26 | -$1.68 | -$1.80 |
| Operating cash flow | -$115.54M | -$105.04M | -$41.42M | -$165.24M |
| Free cash flow | -$115.63M | -$105.93M | -$41.78M | -$165.85M |
| Cash & equivalents | $53.99M | $50.50M | $5.81M | $146.65M |
| Total assets | $122.83M | $116.37M | $93.52M | $186.53M |
| Total liabilities | $52.40M | $113.26M | $129.24M | $159.25M |
| Shareholders' equity | $70.43M | $3.11M | -$35.71M | $27.29M |
| Return on year-end equity | -172.3% | n/m | n/a | -586.6% |
| Shares outstanding | 60.58M | 193.00M | 55.73M | 97.87M |
Revenue, most recent five fiscal years
| Fiscal year | Acumen Pharmaceuticals, Inc. | Humacyte, Inc. | Quince Therapeutics, Inc. | Editas Medicine, Inc. |
|---|---|---|---|---|
| Latest | n/a | $2.04M Ended 2025-12-31 | n/a | $40.52M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | n/a | $32.31M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $78.12M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $19.71M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $25.54M Ended 2021-12-31 |